MYCN and neuroblastoma: High-risk neuroblastomas include stage L1 and L2 tumors with MYCN amplification, stage M in patients younger and older than 18 months of age with MYCN amplification, stage MS in children younger than 18 months with 11q aberration, and stage MS in children younger than 18 months of age with MYCN amplification [30,31].